Pumecitinib

普美昔替尼鼻喷雾剂

Report date: 2026/02/14 20:00:22
NME

Base Information

Drug NamePumecitinib
Drug Alias NamePG-011
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2
Therapy Area/IndicationsRhinitis, Allergic, SeasonalRhinitis, Allergic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPrime Gene Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPrime Gene Therapeutics Co LtdShanghai Primegene Bio-Tech Co Ltd
Inactive CompaniesN/A
Active IndicationsRhinitis, Allergic, SeasonalRhinitis, Allergic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A